NovAccess Global Inc (EM) (XSNX)

Interesting little shell this has turned into.

Nothing says high risk more than 12% interest

This Schedule 13D is filed by David Sumner and Dawn Digital Limited. Mr. Sumner is the sole owner of Dawn Digital.



(b) The business address of Mr. Sumner and Dawn Digital Limited is 85 Great Portland Street, London, England WIW 7LT.



(c) Mr. Sumner is the chief executive officer of Sumner Global, a global company that has created value across a diverse range of assets focusing on the procurement of products and services for governments and corporations around the world with an emphasis on healthcare and logistics.



(d) During the last five years, neither Mr. Sumner nor Dawn Digital Limited has been convicted in any criminal proceeding (excluding traffic violations).



(e) During the last five years, neither Mr. Sumner nor Dawn Digital Limited been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.



(f) Mr. Sumner is a citizen of the United Kingdom and Dawn Digital Limited is a special purpose holding company incorporated in the British Virgin Islands.



Item 3. Source and Amount of Funds or Other Consideration.



On May 17, 2024, Dawn Digital Limited entered into a stock purchase agreement with the Company and sold an 18.6% ownership interest in Fendix Media Limited to the Company in exchange for 14,795,455 newly-issued unregistered shares of the Company’s common stock (the “Shares”).

https://www.sec.gov/Archives/edgar/data/1039466/000118518524000627/sumnerd20240611_sc13d.htm


I'll take a gamble position again.

a special purpose holding company incorporated in the British Virgin Islands.

These puppies have a way of making some bounces happen. On alert for some promo action.

As a fellow shareholder I certainly hope that you're right, but based on a $9,000 loan? I'm hopeful but not very optimistic (yet)...

Mr. Cassarini loaned NovAccess $9,000 on May 31, 2024. The loan is convertible into shares of the company's common stock at $0.11 a share.

https://www.sec.gov/Archives/edgar/data/1039466/000118518524000610/xslF345X05/ownership.xml


TO THE MOON!!!!




LOL

This would call Dr. Dwain Irvin's integrity into question as well, no?

please read the latest 8-k...they admit that they cannot even pay their bills...its like they are robbing paul to pay peter and now they are going down with the ship and still continuing the same racket....there should be a skull and cross bones on this company...

https://www.otcmarkets.com/stock/XSNX/news/NovAccess-Global-Announces-New-License-to-Advance-its-Immunotherapy-Platform?id=438752

this reeks so much of shady criminal neglect. maybe they borrowed a page from universal express usxp....that ceo went to prison,company went into receivership.guy can not ever hold a board position on any company that trades in the usa...

Think the straw boke the camels back here a LONG time ago.

What a horrible read....


https://ih.advfn.com/stock-market/USOTC/novaccess-global-qb-XSNX/stock-news/93215538/form-8-k-current-report

Yeah, thanks, well I noticed they told everyone they would file their IND application in 2023, and I called IR, and they said they hadn’t done it yet. I didn’t ask anymore questions but I’m assuming the delay was the financing, which now … they are financed… so I would assume the IND application is coming.

I just found this about a week ago, so my average is pretty low r now.

Probly doing better than 98% of the others invested here.

I still peek on this once in a while. Thought about buying a huge chunk soon but want to look at the chart 1st. This would be like throwing your money in a fire pit. Might make you warm and fuzzy, till it fizzles out.

Hey Boo, You still watching this ?

Thanks

Volume has been picking up.

Yup

I'd say SIG ( Sumner Investment Group) knows how to let their money work for themselves. Earning 10% a year plus all the extras? Yeah. And their terms make it so theirs like almost no risk to them.
https://www.sec.gov/Archives/edgar/data/1039466/000118518523000952/ex_568262.htm

Any thoughts on today's 8k??

For good and valuable consideration, including the warrant shares (as described below), the receipt and adequacy of which are hereby acknowledged, the Purchaser consents (the “One-time Modifications”) to (i) extend the maturity date of each of the Purchaser Notes to August 31, 2023 and (ii) automatically modify all prior warrants such that each warrant may now be exercised, in whole or in part, at any time by means of a “cashless exercise”. Interest on each of the notes shall accrue and shall be due and payable, together will all other amounts due and owing thereunder on or before August 31, 2023.



In consideration for the foregoing One-time Modifications, the Company shall issue to Purchaser 2,000,000 warrant shares, with an exercise price of $0.20 (pursuant to the warrant in the form annexed hereto).
https://ih.advfn.com/stock-market/USOTC/novaccess-global-qb-XSNX/stock-news/91810259/form-8-k-current-report

Common stock, no par value; 2,000,000,000 authorized common shares

21,535,457 and 18,669,507 shares issued and outstanding, respectively
https://www.sec.gov/ix?doc=/Archives/edgar/data/1039466/000118518523000812/novaccess20230630_10q.htm



At least they won't need to raise the AS.

NEWS from June 16th: NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division

NovAccess Global Inc.
NovAccess Global Inc.
June 16, 2023
In this article:

XSNX
+4.76%
Watchlist

Watchlist
CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced a partnership with Thailand-based CKN Ventures Limited, a multifaceted clinical and commercial healthcare platform, to expand clinical data set access in Southeast Asia to enhance and accelerate personalized therapeutics and treatment protocols. This partnership supports NovAccess Global's new Precision Medicine Division, launched earlier this month, to develop the most comprehensive collection of personalized therapeutics and treatment protocols using artificial intelligence (AI), Big Data and Predictive technologies.

Using advances in AI, image recognition and predictive data science, NovAccess Global and CKN Ventures will collaborate to expand access to relevant data sources in Asia that will improve the quality and impact of licensed databases to identify patient data (phenotypic, clinical, and genomic) for analysis relating to therapeutic drug development and therapeutic treatment purposes. Therapeutic and treatment protocol data will be marketed to external pharmaceutical and biotechnology companies, private payers, national/international health agencies and healthcare providers and insurers.

According to Market.us, the global precision medicine market size was $83.4 billion in 2022 and is projected to reach $254 billion by 2032, exhibiting a compounded annual growth rate of 12.1% in the forecast period (2023-2032). Asia is the fastest growing market in the world for the delivery of innovative care in oncology and immune oncology therapeutics, all of which depend upon management of robust, high-quality data sets to discover new treatment pathways.

Commenting on the latest development to expand the Company's new Precision Medicine Division, NovAccess Global's Chief Executive Officer Dr. Dwain K. Irvin said, "We are very excited to publicly announce our partnership with CKN Venture Limited's world-class team of physicians and data scientists to expand access to critical data streams in Asia to better serve patients facing cancer and other diseases, globally. As part of the initial contributions from CKN, we expect to accelerate and expand our collection of patient data primarily through their glioblastoma database from multiple southeast Asian countries. Furthermore, CKN offers a wide variety of other support services and collaborative opportunities through their basic science and clinical laboratories. Together, we will also have opportunities to bring our technology to Asia and collaborate and develop novel therapeutics and diagnostics."

"Joining forces with NovAccess Global will not just expand the quality of data sources available to both companies and improve our combined geographical reach, but will allow for CKN Ventures to drive a generation of new and enhanced targeted data sets by providing molecular and genomic sequencing capabilities from its Bangkok-based laboratory and wholly owned subsidiary, Phoenix Molecular," said CKN Ventures Director Supornchai Kongpatanakul, MD. "We view CKN's strengths in bioinformatics, molecular diagnostics, and the development of digital health systems to be complimentary to NovAccess Global's assets in therapeutics and precision medicine. Together, the two companies will leverage their combined talents to identify new breakthroughs in cancer and chronic disease management through this unique collaboration."

NovAccess Global intends to also use AI within these data sets to identify the most optimal antigens to use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient.

It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.

In partnering with NovAccess Global, CKN Ventures is positioned to support trials of the Company's therapeutic candidate in glioblastoma patients in both North America and Asia. Dr. Supornchai added, "Our proven capabilities in genomics and bioinformatic analysis will help to support NovAccess Global's trial design and assist in measuring patient response to this groundbreaking therapy while providing research and pharmaceutical entities with data on various variables such as biomarkers and clinical outcomes."

About NovAccess Global

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.

Follow us on social media and stay up to date on all of our developments:

https://www.youtube.com/@novaccess

https://www.facebook.com/novaccessglobal

https://www.linkedin.com/company/64892686

https://twitter.com/novaccessglobal

ABOUT CKN VENTURES, LTD.

CKN Ventures is a group of technology companies based in Thailand with offices and facilities in Thailand and Singapore and serving both ASEAN and international regions. We focus on advanced diagnostics and technology-based precision medicine that enables physicians to deliver personalized care to patients with Cancer and other chronic or infectious diseases. Founded in 2019 we apply advanced technologies and artificial intelligence (AI) to process diverse peer reviewed data (genome, medical test results, medications, lifestyle etc.) on patients and utilize the latest medical research to generate personalized prescriptions/care plans. The personalized care plans go beyond the current standard-of-care and utilize targeted combinations of existing treatments to deliver better patient outcomes for target diseases as well as lowering healthcare costs. Physicians use our care plans as a guide to treat patients uniquely based on analysis including a battery of existing clinical tests, their genome, and their disease status, and do so in a fast and economical package.

Our initial products address the spectrum of cancers with a personalized combination therapy which deliver better patient outcomes than the standard-of-care. Physicians are provided with a detailed and comprehensive report which outlines individual genomic details and suggests the most appropriate therapies to administer based on individual genetic analysis. The AI based software which creates Physician Reports is regularly updated as new therapeutic techniques and drugs are constantly being developed, published, and approved.

CKN also owns and manages registered diagnostic labs outfitted with State-of-the-Art equipment and highly trained personnel. We have a catalogue of esoteric molecular and immunological diagnostic assays and also create and develop our own "LDT's" (Lab Developed Tests), including reagents, testing formats, and equipment/automation.

The Company is also developing a distribution network to sell the diagnostic kits and processes we acquire and develop to hospitals and clinical lab networks throughout ASEAN countries. We are creating a combination of in-house sales force and large regional corporate partnerships for distribution of registered kits and select genomic sequencing services for cancers. CKN also is highly experienced in Regulatory Approvals and running Clinical Trials.

Forward-Looking Statement for for NovAccess Global

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

Investor Relations Contact for NovAccess Global:

Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com

Contact for CKN Ventures:

Supornchai Kongpatanakul, M.D.
+66 81 836 7987
supornchai@cknventures.com

SOURCE: NovAccess Global Inc.



View source version on accesswire.com:
https://www.accesswire.com/761806/NovAccess-Global-Partners-with-CKN-Ventures-to-Expand-its-New-AI-driven-Precision-Medicine-Division




Anything can happen.
All it takes is the right person to hold their hand and for them to listen.

Prob not...

This stock was recommended to me several years ago by a friend in Ohio. He said it was a 'thin trader' in a viable sector of the market and was susceptible to rapid price swings in either direction--but a good long term investment due to their (then) upcoming medical patents if you have the patience of Job and you only use spare money to buy shares of it...

Back then I bought roughly 2500 shares, but I eventually grew disenchanted with what I perceived as administrative incompetence...So I sold my meager holdings and never looked back again until today, and I notice that the share price has cratered all the way down to 11 cents...

Does anyone here still see XSNX as worth buying?

Just curious,
C

Hmmm. Just a hunch something is coming up soon. Gotta be right? Time passages.

Looks good today on low vol, watching

Unfortunately...

Looks like XSNX is owning up to owing a shortfall since the price has depreciated so much. Simply covering for more dilution.

JMHO.

See the modification/adjustment filing.

https://www.sec.gov/Archives/edgar/data/1039466/000118518523000060/ex_466623.htm

What do you make of this?

https://ih.advfn.com/stock-market/USOTC/novaccess-global-qb-XSNX/stock-news/90039639/current-report-filing-8-k

Item 1.01 Entry into a Material Definitive Agreement.

NovAccess Global Inc., a Colorado corporation (“NovAccess” or the “company”), previously entered into three securities purchase agreements dated August 20, 2021, February 15, 2022, and May 5, 2022 (collectively, the “Agreements”), with AJB Capital Investments, LLC (“AJB”). Pursuant to the Agreements, NovAccess issued promissory notes to AJB representing loans provided by AJB to the company totaling $1.75 million. Also pursuant to the Agreements, NovAccess paid AJB commitment fees totaling 1,575,000 unregistered shares of the company’s common stock (the “commitment fee shares”). If AJB is unable to sell the commitment fee shares for amounts specified in the Agreements, then AJB may require NovAccess to issue additional shares or pay cash in the amount of the shortfall (the “make-whole rights”). However, AJB may only exercise its make-whole rights within time frames following the loan dates specified in the Agreements (the August 20, 2021 and February 15, 2022 make-whole rights each have a term of 18 months and the May 5, 2022 make-whole rights have a term of 36 months). The August 20, 2021 make-whole rights expire on February 20 of this year. To avoid forcing AJB to sell the commitment fee shares in order to take advantage of its make-whole rights, on January 20, 2023 NovAccess entered into a letter agreement with AJB extending the exercise period for the make whole-rights to 72 months. As amended by the letter agreement, the make-whole rights now expire on August 20, 2027, February 15, 2028, and May 5, 2028. The letter agreement makes additional less material revisions to AJB’s make-whole rights and harmonizes the make-whole rights among the Agreements.

The letter agreement with AJB is filed as an exhibit to this Current Report on Form 8-K. The description above is qualified in its entirety by reference to the full text of the agreement.

8K yesterday.....

Something smells fishy here....

Thanks - I will get familiar with XSNX over the weekend.

They've got things happening, just not getting their name out there.

Going to read the board over the weekend.

Anything to see here?

Thanks

NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1

NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1

FDA Expands the Scope of the Company's Submission

Accelerates Path Toward Immunotherapy for Glioblastoma (Brain Cancer)

CLEVELAND, OH / ACCESSWIRE / October 26, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas.

https://finance.yahoo.com/news/novaccess-global-receives-fda-approval-110000523.html

NovAccess Global Announces Fireside Chat with Board Member Perspectives
9:18 am ET October 20, 2022 (Accesswire) Print
Topic: Opportunities for the Biomedical Field and for Shareholders

CLEVELAND, OH / ACCESSWIRE / October 20, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its initial installment in a series of interviews with its corporate leadership on a monthly basis for the next four months, with additional sessions to be made available as company developments arise. Interviews are intended to cover important and timely topics relating to the Company, its platform technologies and the global healthcare and business environments.

The initial fireside chat includes interview with select Executive and Non-Executive members of the Company's Board of Directors. The interview is being streamed for public viewing over the Internet and can be accessed via the News tab of the Investors section of the NovAccess Global website at https://novaccessglobal.com/news/ and on all of the Company's social media feeds.

During the interview made available today, Company speakers address:

NovAccess Global advancing where no measurable survivability and quality of life improvements have been achieved in 50 years for glioblastoma/brain tumors
Significant unmet need in the glioblastoma/brain tumor market
Progress pathways for NovAccess Global's novel lead product TLR-AD1, including IND and FDA data submissions
Representing a new class of immunotherapies shaping the industry
Enhanced response and survival potential using the Company's patented platform-based immune booster technology
Driving efficiencies with check point inhibitors for improving tumor treatment outcomes
Aggressive timeline set to achieve inflection points of safety and efficacy for lead product
Licensing opportunities for various cancer treatments
Accelerating healthcare innovation through technology transfer
Exponential value creation potential for investors available through NovAccess Global
Speaker Bios:

Dr. Dwain Irvin, Ph.D., MPH, CEO and Executive Board Member of NovAccess Global -- Dr. Irvin is an active participant in many Biotechnology and Health Science endeavors and is an expert including patent generation in such areas as treatments for Parkinson's, brain cancer, and even cosmetic application of advanced bioscience. He is also an expert in the physical operations of laboratories, and hospitals. He received his Ph.D. from UCLA School of Medicine, and Masters in Public Health from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.

Dr. Irvin's Ph.D. is in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells.

He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson's disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells.

Additionally, Dr. Irvin led research investigations in the role of adaptive immunity in Parkinson's disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized this data to develop novel immunotherapies for brain tumor patients.

John Cassarini, Board Member of NovAccess Global -- Mr. Cassarini has spent the last three decades working with and investing in small-cap companies. He began his career on Wall Street as an Associate in the Equity Research Department of Smith Barney. Later, he joined Smith Barney's parent company, the Travelers Corporation, as an analyst responsible for private and public investments in emerging businesses. In addition, he worked as a portfolio manager at several institutions, including Ingalls & Snyder, Lehman Brothers, and Barclays Capital, managing funds focused on small emerging growth companies.

Mr. Cassarini graduated from Fordham University with a bachelor's degree in finance and a master's degree in business administration from Columbia University.

Jason Anderson, Board Member of NovAccess Global --Mr.Anderson is experienced in the fields of biological discovery, genomic modeling, drug development, and national security. From 2016-2020, he was a co-founder and member of the board of EdenRoc Sciences, LLC, a privately-held biotechnology company formed to cultivate world-class life sciences start-up companies to include Liberty BioSecurity, LLC, where he served as co-founder and Chief Executive Officer from 2014-2020. This integrated life sciences platform leveraged a dynamic intellectual property portfolio spanning pharmaceuticals, novel biology, genomics, and molecular diagnostics.

From 1998 to 2014, Mr. Anderson served as a diplomat for the United States Department of State. He has co-authored several granted patents in the life sciences and speaks on international affairs and biotechnology innovation. He is a graduate of the London School of Economics and Political Science and the University of California, San Diego, and speaks Spanish and Chinese (Mandarin).

NovAccess Global Fireside Chat Series Schedule:

The series will include interviews on a monthly basis over the next four months. Interviews will be made available by NovAccess Global as detailed below:

October 6, 2022 - NovAccess Global Board Member Perspectives - Opportunities for the Biomedical Field and for Shareholders

Speakers: Select Executive and Non-Executive members of the Company's Board of Directors

November 3, 2022 - Patient Advocacy

Speaker: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global

December 1, 2022 - Immunotherapy Advantages Over Surgical Treatment

Speaker:Dr. Christopher Wheeler, Ph.D., President of StemVax Therapeutics Inc., a division of NovAccess Global

January 5, 2023 - The Glioblastoma and Brian Tumor Market

Speaker: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global

The interviews will be streamed for public viewing over the Internet and can be accessed on the dates provided in this press release through links made available on the NovAccess Global website at www.novaccessglobal.com and on all of the Company's social media feeds.

About NovAccess Global

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.

Forward-Looking Statement

This press release contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

This press release and the interviews to be published as part of the NovAccess Global fireside chat series are for informational purposes only and should not be considered investment advice, an offer to sell, or a solicitation of an offer to buy any security. Interview participants have agreed to participate in this event series and no compensation will be paid or furnished to them or their respective organizations. Participation does not represent an offer to buy or sell any security to or from any person or other entity through their platforms. Prior to making any investment or subscribing to any of the platforms that may be associated with the fireside chat series and re-distribution of related content, listeners/viewers are encouraged to consult with professional financial, legal advisor and tax advisors to assist in due diligence as may be appropriate in determining the risk associated with any investment.

Investor Relations Contact:

Jordan Darrow

Darrow Associates

631-766-4528

jdarrow@darrowir.com

SOURCE: NovAccess Global Inc.

Read the 8K and understand the dilution this is facing and the discount they get. Yes, this is toxic funding. Only if they can somehow manage to keep retail buying until they're out, I do expect this to depreciate. Possibly significantly.

Welcome to what dark side?

What about the interview with Dr. Irwin gives you pause, if anything?
C

I'm a small-fry investor with a minor stake in this company based on the uniqueness of their approach to the treatment of glioblastoma and other potentially lethal cancers...

So what are you saying here--that you expect the stock price to drop to a penny?

If so, why??

End,
C

Thinking .01 until they file their IND. 35% discount on their financing with a 15 day VWAP, it won't take long to tank this.

Whelp, welcome to the dark side.

https://ih.advfn.com/stock-market/USOTC/novaccess-global-qb-XSNX/stock-news/89178972/current-report-filing-8-k

https://novaccessglobal.com/news/ Some good stuff in there. And now they're OTCQB. Looking for their IND soon.

Also...
NovAccess Global expects to submit an Investigational New Drug (IND) application to the FDA
for TLR-AD1 by the first quarter of 2023. In advance of the IND filing, the Company expects to
announce a partnership with a clinical manufacturing organization for vaccine testing and
production readiness for phase I-II clinical trials of TLR-AD1
https://novaccessglobal.com/wp-content/uploads/2022/07/NovAccess-Global-Orphan-Drug-Application-Filing-071922-1.pdf
.

They are just not getting noticed imo.

With that news, it's a shame this isn't on Nasdaq

NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
Tue, July 19, 2022, 9:00 AM
In this article:

XSNX
+57.8947%

Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer)

CLEVELAND, OH / ACCESSWIRE / July 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the filing of an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma multiforme (GBM) and other high grade gliomas.

GBM is a form of aggressive brain cancer that annually impacts approximately 250,000 people globally and is on the rise in many countries, according to NovAccess scientists and published reports. The market data is more alarming, with GBM accounting for approximately 50% of all malignant brain cancers diagnosed in the United States each year, and more than 10,000 Americans dying from this tumor type annually. Less than 5% of people with this cancer live longer than 5-years after their diagnosis. The global GBM treatment market was estimated to be valued in excess of $2 billion in 2020, with projections for a compounded annual growth rate of more than 8% throughout the remainder of the decade.

"We are very excited to announce the filing of an Orphan Drug application for TLR-AD1 as it may lead to the granting of special status and enable the acceleration of the development of our therapies to treat multiple forms of glioblastomas," said Dr. Dwain Irvin, Chief Executive Officer of NovAccess Global. "The ODD process supports the development and evaluation of new treatments for rare diseases which is a key priority for both the FDA and for NovAccess Global. Receiving this important designation would represent a milestone in the development of TLR-AD1 and would highlight the need for potential new treatment options for patients with aggressive brain cancers which today have no immunotherapy treatment leaving only the option of highly invasive and complicated surgery."

Dr. Irvin continued, "Upon receiving ODD, the product will significantly bolster NovAccess Global's intellectual property portfolio, which presently includes the rights to U.S. patent #US9764014B2 granted under the "Cancer Antigens" category related to the "treatment of cancer using vaccination therapy." We are pleased with the progress we are making toward building out our platform for novel immunotherapy for brain tumor patients."

The FDA's Office of Orphan Products Development grants orphan designation status to investigational drugs and therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug designation provides benefits to drug developers which may include assistance in the drug development process, financial incentives to support clinical development, tax credits for clinical costs, exemptions from certain FDA fees and the potential for seven years of post-approval marketing exclusivity.

Sponsors seeking orphan drug designation for a drug must submit a request for designation to the FDA. Orphan drug designation is a separate process from seeking commercial approval or licensing. As such, the receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.

About TLR-AD1

TLR-AD1 is designed to activate anti-tumor immune responses against these brain tumors using immune-activating dendritic cells combined with the patient's own tumor proteins. The resulting dendritic cell vaccines are matured with a proprietary combination of Toll-like receptor (TLR) adjuvants to boost their immune-activating potency beyond current vaccine preparations.

NovAccess Global expects to submit an Investigational New Drug (IND) application to the FDA for TLR-AD1 by the first quarter of 2023. In advance of the IND filing, the Company expects to announce a partnership with a clinical manufacturing organization for vaccine testing and production readiness for phase I-II clinical trials of TLR-AD1.

About NovAccess Global

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. The Company owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.

Forward-Looking Statement

This email and its attachments contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission and/or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

Investor Relations Contact:

Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com

SOURCE: NovAccess Global Inc.



View source version on accesswire.com:
https://www.accesswire.com/708956/NovAccess-Global-Announces-Filing-of-Orphan-Drug-Application-for-TLR-AD1

Makes one wonder. And I didn't even watch their presentation.

A 47% day. Hmmmmm

On December 30, 2021, NovAccess Global Inc. (“NovAccess” or the “company”) obtained a $25,000 loan from each of Dwain K. Morris-Irvin, the company’s chief executive officer, Neil J. Laird, the company’s chief financial officer, and Amit Mulchandani, chief executive officer of Letzhangout, LLC, a company that provides accounting consulting services to NovAccess (collectively, the “Loans”). NovAccess issued to each of Messrs. Irvin, Laird and Mulchandani a demand promissory note for $25,000 evidencing the Loans (Collectively, the “Notes”). The Notes are due on demand and bear interest at 10% per year. NovAccess will use the $75,000 proceeds of the Loans to retire the loan from Power Up Lending Group Ltd. and for general working capital purposes.

https://ih.advfn.com/stock-market/USOTC/novaccess-global-pk-XSNX/stock-news/86928970/current-report-filing-8-k

See yesterday's 8k. 25k for 10% interest per year divi? And going debt free for the company? That's a pretty good start imo.

Yes, I'm still here.

Guess we'll wait for the penny. Or lower.

NovAccess Global, Inc. Names Neil Laird, Chief Financial Officer
Wed, December 8, 2021, 9:00 AM
In this article:

XSNX
-31.98%

Explore the topics mentioned in this article

CLEVELAND, OH / ACCESSWIRE / December 8, 2021 / NovAccess Global, Inc. (OTC PINK:XSNX) welcomes new Chief Financial Officer (CFO), Neil Laird.

"I am pleased to welcome Neil Laird to the management team," said Dr. Dwain Irvin, Chief Executive Officer, NovAccess Global.

Neil J. Laird is an experienced financial executive who works with emerging companies to provide accounting and finance-related services. Since 2017, he has worked with several technology and other companies as a consultant. Before that, he was the Chief Financial Officer of Mobileum Inc., a private company providing roaming and other solutions to the telecommunications industry. Prior to this, he was Chief Financial Officer at SumTotal Systems, a provider of enterprise learning management systems and before that, Chief Financial Officer at ADAC Laboratories, a provider of nuclear medicine and PET systems. Both were publicly traded companies. He also held senior management positions at Coherent Medical Lasers and Measurex Corporation. Mr. Laird has an MA from the University of Cambridge and qualified as a UK chartered accountant.

We thank ex-Chief Financial Officer, Mike Yukich who came out of retirement and helped NovAccess Global spin-off from the parent company Innovest Global.

About NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our company has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. The company owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.

Forward-Looking Statement
This press release and its attachments contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the company's disclosures or filings with the Securities Exchange Commission and/or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

Investor Relations Contact:
Satya Chillara
Darrow Associates
(510) 396 -2776
schillara@darrowassociates.com

SOURCE: NovAccess Global Inc.

https://finance.yahoo.com/news/novaccess-global-inc-names-neil-140000350.html



We'll see if they can get their feet off the ground soon. My thinking anyway.